BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Despite widespread use of combination medical therapy for BPH\, patients experience varying levels of symptom relief\, the burden of taking multiple medications daily\, and negative effects on sexual function.1\,2 As minimally invasive surgical therapies (MISTs) evolve\, urologists require high-quality comparative data to inform shared decision-making with patients\, particularly for patients eligible for Rezūm Therapy under expanded indications.\n\nJoin this engaging talk with Dr. Kevin McVary\, a global leader in BPH care\, as he discusses new developments in data surrounding Rezūm Therapy as a first-line alternative to combination drug therapy. Dr. McVary will discuss recent publications including Rezūm vs the MTOPS Trial\, as well as prospective data from the VAPEUR Randomized Controlled Trial\, and what they mean for urologists and their patient care.\n\nSaturday\, May 16\n11:30–11:55 a.m. ET\nBooth 2161\nDr. Kevin McVary\nProfessor and Director Center for Male Health Stritch School of Medicine Loyola University Medical Center\n\nPresenters are paid consultants for Boston Scientific and are compensated for their participation.\n
X-ALT-DESC;FMTTYPE=text/html:Despite widespread use of combination medical therapy for BPH, patients experience varying levels of symptom relief, the burden of taking multiple medications daily, and negative effects on sexual function.1,2 As minimally invasive surgical therapies (MISTs) evolve, urologists require high-quality comparative data to inform shared decision-making with patients, particularly for patients eligible for Rezūm Therapy under expanded indications.<br><br>Join this engaging talk with Dr. Kevin McVary, a global leader in BPH care, as he discusses new developments in data surrounding Rezūm Therapy as a first-line alternative to combination drug therapy. Dr. McVary will discuss recent publications including Rezūm vs the MTOPS Trial, as well as prospective data from the VAPEUR Randomized Controlled Trial, and what they mean for urologists and their patient care.<br><br>Saturday, May 16<br />11:30–11:55 a.m. ET<br />Booth 2161<br />Dr. Kevin McVary<br /><em>Professor and Director Center for Male Health Stritch School of Medicine Loyola University Medical Center<br /></em><br /><em>Presenters are paid consultants for Boston Scientific and are compensated for their participation.<br /></em>
UID:1778999062addeventcom
SUMMARY:Redefining the BPH Treatment Algorithm — Emerging Data on Rezūm™ Water Vapor Therapy as a First-Line Alternative to Medications
DTSTART;TZID=America/New_York:20260516T113000
DTEND;TZID=America/New_York:20260516T235500
DTSTAMP:20260517T062422Z
TRANSP:OPAQUE
STATUS:CONFIRMED
SEQUENCE:0
LOCATION:Booth 2161
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
BEGIN:VALARM
TRIGGER:-PT30M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR